Narcolepsy Market to Reflect Impressive Growth Rate by 2027

1
Narcolepsy Market
Narcolepsy Market to 2027 - Global Analysis and
Forecasts by Type (Narcolepsy with Cataplexy,
Narcolepsy without Cataplexy, and Secondary
Narcolepsy) Product (Central Nervous System
(CNS) Stimulants, Sodium Oxybate, and
Antidepressants) Distribution Channel (Hospital
Pharmacies and Retail Pharmacies) and Geography
2
Market Scope
Narcolepsy Market

• The global narcolepsy market accounted to US
  2,026.8 Mn in 2018 and is expected to grow at a
  CAGR of 9.5 during the forecast period 2019
  2027, to account to US 4,537.9 Mn by 2027.
• The Asia Pacific narcolepsy market is expected to
  grow at highest rate during the forecast period
  owing higher number of research development and
  increasing investments on sleep related
  neurological disorders. In addition, emergence of
  new local players with competitive drug portfolio
  are expected to fuel the market growth in Asia
  Pacific region.

3
Market Segments
Narcolepsy Market
4
Factors Contributing to Market Growth
Narcolepsy Market

• Rising prevalence of sleep related neurological
  disorders is expected to boost the market growth
  over the years
• Increasing Awareness Regarding Neurological
  Disorders
• The relationship between public health and
  neurology was not been adequately explored until
  recent years. The burden of neurological
  disorders have increased significantly across the
  world. These disorders are estimated to affect
  over a billion population worldwide, according to
  the World Health Organization by 2016.
  Neurological disorders are commonly found among
  all the age groups, in all geographic populations.

5
Narcolepsy Market
Strategic Insights
Strategic acquisition and product launches were
observed as the most adopted strategy in global
narcolepsy industry. Few of the recent product
launch and acquisitions are listed below   2018
Jazz Pharmaceuticals announced FDA approval of
Xyrem (sodium oxybate) for the treatment of
cataplexy or excessive daytime sleepiness in
pediatric narcolepsy patients 2019 Takeda
Pharmaceutical Company Limited acquired Shire plc
to expand its geographic footprint and leading
position in Japan and the U.S. 2018 Jazz
Pharmaceuticals announced FDA acceptance of
supplemental new drug application for Xyrem
(sodium oxybate) to treat cataplexy and excessive
daytime sleepiness in pediatric narcolepsy
patients
For more details, get sample PDF copy
https//www.theinsightpartners.com/sample/TIPRE000
03326/
6
Leading Players
Narcolepsy Market

• Bioprojet
• Teva Pharmaceutical Industries Ltd.
• Jazz Pharmaceuticals, Inc.
• Graymark Healthcare, Inc.
• Arena Pharmaceuticals, Inc.
• Shire (Acquired by Takeda)
• Ligand Pharmaceuticals, Inc.
• Novartis AG
• Mylan N.V.
• Shionogi Inc.

7

A report titled Narcolepsy Market -
Opportunities and Forecasts, 2018 2027 has
been recently published by The Insight Partners.
The report makes close observations of pipeline
structure for end-to-end market around the world.
It makes an in-depth analysis of current trends,
drivers, and restraining factors that affect
financial ratios relevant to the industry.
Company profiles for key vendors in business
builds a comprehensive picture of profitable
opportunities from stakeholders perspective.

To know more about the Narcolepsy Market -
Opportunities and Forecasts, 2018 2027 report
https//www.theinsightpartners.com/reports/narcole
psy-market
Follow us on
Thank You